| Vernon Green Nursing Home | |
| 61 Greenway Drive, Vernon, Vermont 05354 | |
| (802) 254-6041 | |
| Name | Vernon Green Nursing Home |
|---|---|
| Location | 61 Greenway Drive, Vernon, Vermont |
| Certified By | Medicare and Medicaid |
| No. of Certified Beds | 60 |
| Occupancy Rate | 68.83% |
| Medicare ID (CCN) | 475008 |
| Legal Business Name | Vernon Advent Christian Home, Inc. |
| Ownership Type | Non Profit - Corporation |
| NPI Number | 1902895287 |
| Organization Name | VERNON ADVENT CHRISTIAN HOME, INC. |
| Doing Business As | VERNON GREEN NURSING HOME |
| Address | 61 Greenway Drive, Vernon, VT 05354 |
| Phone Number | 802-254-6041 |
News Archive
Eli Lilly and Company's investigational compound ruboxistaurin may reduce vision loss from diabetes-induced eye disease, according to new analyses of previously reported data presented at the 2004 Joint Meeting of the American Academy of Ophthalmology and the European Society of Ophthalmology in New Orleans, La.
Medical researchers at the University of Alberta reviewed the medical records of more than 100 patients who had a liver scarring condition and discovered those who were losing muscle were more apt to die while waiting for a liver transplant. These cirrhosis patients were placed at a lower spot on the transplant list because they had a higher functioning liver and were seemingly less sick than others with the same condition, based on scoring systems physicians commonly use today.
Veran Medical Technologies announced today that it received clearance (K091934) from the U.S. Food and Drug Administration (FDA) to market a product for the delivery of instruments through the pulmonary tract. "Veran is excited about this clearance as it allows the company to address a huge unmet clinical need in lung cancer diagnosis and treatment," said Jerome R. Edwards, Veran president and chief executive officer.
Imagine that you have been in combat and that you have watched your closest friend die in front of you.
› Verified 6 days ago
| Ratings from Surveys (Inspections): | |
| Ratings from Quality Measures: | |
| Ratings from Staffing Data: | |
| Overall Rating: |
|---|
News Archive
Eli Lilly and Company's investigational compound ruboxistaurin may reduce vision loss from diabetes-induced eye disease, according to new analyses of previously reported data presented at the 2004 Joint Meeting of the American Academy of Ophthalmology and the European Society of Ophthalmology in New Orleans, La.
Medical researchers at the University of Alberta reviewed the medical records of more than 100 patients who had a liver scarring condition and discovered those who were losing muscle were more apt to die while waiting for a liver transplant. These cirrhosis patients were placed at a lower spot on the transplant list because they had a higher functioning liver and were seemingly less sick than others with the same condition, based on scoring systems physicians commonly use today.
Veran Medical Technologies announced today that it received clearance (K091934) from the U.S. Food and Drug Administration (FDA) to market a product for the delivery of instruments through the pulmonary tract. "Veran is excited about this clearance as it allows the company to address a huge unmet clinical need in lung cancer diagnosis and treatment," said Jerome R. Edwards, Veran president and chief executive officer.
Imagine that you have been in combat and that you have watched your closest friend die in front of you.
› Verified 6 days ago
| Number of Facility Reported Incidents | 0 |
| Number of Substantiated Complaints | 0 |
| Number of Fines | 0 |
| Total Amount of Fines in Dollars | $0 |
| Number of Payment Denials | 0 |
| Total Number of Penalties | 0 |
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Percentage of long-stay residents whose need for help with daily activities has increased | 19.14 | 14.46 |
| Percentage of long-stay residents who lose too much weight | 3.59 | 5.51 |
| Percentage of low risk long-stay residents who lose control of their bowels or bladder | 64.81 | 48.41 |
| Percentage of long-stay residents with a catheter inserted and left in their bladder | 5.13 | 1.79 |
| Percentage of long-stay residents with a urinary tract infection | 9.41 | 2.65 |
| Percentage of long-stay residents who have depressive symptoms | 39.88 | 5.05 |
| Percentage of long-stay residents who were physically restrained | 0 | 0.23 |
| Percentage of long-stay residents experiencing one or more falls with major injury | 3.53 | 3.36 |
| Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 97.65 | 93.87 |
| Percentage of long-stay residents who received an antipsychotic medication | 24.12 | 14.2 |
| Percentage of short-stay residents assessed and appropriately given the pneumococcal vaccine | 89.8 | 83.88 |
| Percentage of short-stay residents who newly received an antipsychotic medication | 0 | 1.79 |
| Percentage of long-stay residents whose ability to move independently worsened | 21.7 | 17.09 |
| Percentage of long-stay residents who received an antianxiety or hypnotic medication | 28.74 | 19.7 |
| Percentage of high risk long-stay residents with pressure ulcers | 1.47 | 7.32 |
| Percentage of long-stay residents assessed and appropriately given the seasonal influenza vaccine | 98.38 | 95.98 |